National Association of Epilepsy Centers

  • Member Login
  • Join NAEC
  • About NAEC
    • Overview
    • Membership Benefits
    • Board of Directors & Staff
  • About Epilepsy Centers
    • Find an Epilepsy Center
    • What is an Epilepsy Center?
    • Guidelines for Centers
    • Accreditation Process
    • NIH & VA Epilepsy Centers
    • NAEC Centers with ABRET LAB-LTM
  • For Patients
    • How an Epilepsy Center Can Help
    • Common Questions
    • Patient Resources
  • For Members
  • NAEC News and Updates
    • NAEC News and Updates
    • Center Resources
    • Featured
    • NAEC Activities
    • News
    • News & Activities
    • Policy Analysis
  • Contact
  • Member Login
  • Join NAEC

NAEC News and Updates

Medicare Final Rule on Medicare Advantage and Part D Drug Pricing

  • May 20 2019
  • Featured, News & Activities
  • Share:

Protected Class Policy for AEDs Maintained in Medicare Part D Final Rule

On May 16, 2019 the Centers for Medicare and Medicaid Services (CMS) published its final rule on Medicare Advantage and Part D Drug Pricing. The final rule did not move forward on CMS’ proposals made earlier this year to weaken the current policies under Medicare Part D for the protected classes of drugs, which include anticonvulsants. The final rule codifies the existing policy that permits Part D plans to impose prior authorization and step therapy requirements only for patients initiating treatment (i.e., new starts), but does not allow Part D plans to impose these utilization management tools with patients already on anticonvulsant medications. In addition, the rule did not finalize the proposals to exclude a protected class drug from a formulary for a price increase above a certain threshold or if the drug represents a new formulation of an existing single source drug.

NAEC submitted a comment letter in opposition to the proposed rule in January and joined many epilepsy organizations in signing a group letter making similar arguments. NAEC argued that the current protected class policies for anticonvulsants be maintained, since so many individuals with epilepsy do not respond to a single drug and an unrestricted formulary providing multiple medication options with novel mechanisms of action and side effect profiles is essential to control seizures and minimize side-effects.

  • Share:
  • Previous
  • Next

Categories

  • Center Resources
  • Featured
  • NAEC Activities
  • News
  • News & Activities
  • Policy Analysis

What is an Epilepsy Center?

Epilepsy centers provide a comprehensive team approach to the diagnosis and treatment of epilepsy.

Learn More

Find an Epilepsy Center

If you are living with seizures or side-effects, an epilepsy center can help.

Find a Center
NAEC - National Association of Epilepsy Centers
  • Mail: 1150 Connecticut Avenue NW, Suite 803, Washington, DC 20036
  • Phone: 202-800-7074
  • Fax: 202-484-1244
  • Email: info@naec-epilepsy.org
  • Privacy Policy
  • Disclaimer
  • Website Credits
© 2022 National Association of Epilepsy Centers